Last reviewed · How we verify

Fentanyl TAIFUN — Competitive Intelligence Brief

Fentanyl TAIFUN (Fentanyl TAIFUN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic (synthetic opioid). Area: Pain Management.

phase 3 Opioid analgesic (synthetic opioid) Mu-opioid receptor (OPRM1) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Fentanyl TAIFUN (Fentanyl TAIFUN) — Akela Pharma, Inc.. Fentanyl TAIFUN is a transdermal or inhalation formulation of fentanyl, a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fentanyl TAIFUN TARGET Fentanyl TAIFUN Akela Pharma, Inc. phase 3 Opioid analgesic (synthetic opioid) Mu-opioid receptor (OPRM1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic (synthetic opioid) class)

  1. Akela Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fentanyl TAIFUN — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl-taifun. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: